Phenotypes Associated with This Genotype

Genotype
MGI:7596100

• Allelic Composition: Nudt15^em1Maska/Nudt15^em1Maska
• Genetic Background: C57BL/6-Nudt15^em1Maska

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

premature death ( J:285800 )

• median lifespan of 21-26 days or 15-21 days after 1 or 2 mg/kg mercaptopurine (MP) administration, respectively

• minimum 70 day survival after 0.2 mg/kg mercaptopurine (MP) administration

hematopoietic system

decreased bone marrow cell number ( J:285800 )

• reduced number of nucleated BM cells after 5 days of 5 mg/kg mercaptopurine (MP) administration

decreased neutrophil cell number ( J:285800 )

• after 14 days of 1 or 7 or 14 days of 2 mg/kg mercaptopurine (MP) administration

• normal after 70 days of 0.2 mg/kg mercaptopurine (MP) administration

decreased hematopoietic stem cell number ( J:285800 )

• after 5 days of 2 or 5 mg/kg mercaptopurine (MP) administration

pancytopenia ( J:285800 )

• after 14 days of 1 or 2 mg/kg mercaptopurine (MP) administration

decreased hematopoietic precursor cell number ( J:285800 )

• reduced after 5 days of 2 mg/kg mercaptopurine (MP) administration

immune system

decreased neutrophil cell number ( J:285800 )

• after 14 days of 1 or 7 or 14 days of 2 mg/kg mercaptopurine (MP) administration

• normal after 70 days of 0.2 mg/kg mercaptopurine (MP) administration

growth/size/body

growth/size/body region phenotype ( J:285800 )

N • normal esophagus, stomach, intestines, liver, lungs, and kidneys after 5 days of 5 mg/kg mercaptopurine (MP) administration

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
leukopenia		DOID:615		J:285800
neutropenia		DOID:1227		J:285800
pancytopenia		DOID:12450		J:285800